Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Yvette L KasamonRichard F Ambinder

Abstract

Autologous blood or marrow transplantation (ABMT) for low-grade lymphomas can prolong event-free survival (EFS) but requires long-term follow-up. We report one of the longest follow-ups to a prospective transplantation study in such diseases. On a phase II study, 80 patients with low-grade, transformed, or mantle cell lymphoma received ABMT with 4-hydroperoxycyclophosphamide (4-HC) purging as part of initial or salvage therapy. Diagnoses included nontransformed follicular lymphoma in 63% and transformed lymphoma in 15%. With 16.6-year median follow-up for survival, actuarial 10-year EFS and overall survival (OS) were 34% (95% confidence interval [CI], 25%-46%) and 45% (35%-57%). Median EFS and OS were 3.0 and 8.0 years. Early nonrelapse mortality incidence was 8%; myelodysplastic syndrome or leukemia incidence was 4%. Most relapses occurred within 3 years, with a median time to diagnosis of relapse of 1.8 years (range: 0.1-15.6 years). On multivariate analysis, age >50 years, ≥3 prior chemotherapy regimens, and ABMT after relapse were associated with significantly inferior survival. Fifteen patients (19%) were event-free >15 years after transplantation, raising the possibility of a plateau in the progression-free survival curve...Continue Reading

References

May 23, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ama Z S RohatinerArnold S Freedman
Jul 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mitchell SabloffLothar B Huebsch
Aug 19, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jennifer R BrownArnold S Freedman
Dec 27, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Julie M VoseJames O Armitage
Jan 4, 2008·Cancer Research·William MatsuiRichard J Jones
Jan 31, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M KornackerP Dreger
Feb 4, 2009·Blood·Richard J JonesWilliam Matsui
Sep 30, 2009·Nature Reviews. Clinical Oncology·Ashkan EmadiRobert A Brodsky
Nov 3, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y L KasamonI W Flinn

❮ Previous
Next ❯

Citations

Feb 9, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B MetznerC H Köhne
May 31, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nishitha Reddy, Bipin N Savani
Sep 21, 2016·Cancer Chemotherapy and Pharmacology·Martina Ahlmann, Georg Hempel
Jun 25, 2017·Chemico-biological Interactions·Maura Gasparetto, Clayton A Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.